Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model
New data demonstrates superior potency of nimacimab's differentiated and favorable mechanism of inhibition versus monlunabant
Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated:
Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide
Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone.
'This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor—nimacimab—effectively drives weight loss in a DIO model. Nimacimab compared favorably to and provided significant additive weight loss when combined with GLP-1-targeted drugs like tirzepatide,' said Punit Dhillon, CEO of Skye. 'Using higher doses, this study builds on our previous preclinical DIO data in human CB1 knock-in mice that showed significant dose-dependent weight loss. Biomarker analyses demonstrated that nimacimab-driven weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers.
'Skye believes nimacimab shows potential both as a monotherapy and in combination with a GLP-1 targeted drug to address unmet needs in obesity with the potential to change weight loss standards of care. Initial data from Skye's Phase 2a study in obesity is expected in late Q3/early Q4 2025.'
Mr. Dhillon added, 'The second key finding of this animal study is that Skye's highly-peripherally restricted nimacimab drives efficacy similar to a less-peripherally restricted CB1 inhibitor, monlunabant, in a DIO model. These in vivo data continue to support our belief that our differentiated antibody approach can potentially provide meaningful efficacy without the challenge current small molecule CB1 inhibitors face—brain exposure that can cause unwanted neuropsychiatric side effects.'
Figure 1 - DIO model to interrogate combination of nimacimab and tirzepatideNew In Vitro Data Characterizes Differentiated Potency Characteristics
Skye also shared new in vitro potency data demonstrating that nimacimab's non-competitive allosteric binding to CB1 provides for a differentiated and potentially advantageous mechanism of inhibition versus small molecules like monlunabant, which must compete with CB1 agonists. In this study, potency of nimacimab and monlunabant were assessed against two concentrations of the CB1 agonist CP55940. The first condition evaluated potency of each drug with a lower concentration of CP55940 (50nM or EC80), while the second condition evaluated potency against an elevated concentration of CP55940 (2000nM or 40X EC80). These two conditions serve as a model of a physiological versus a pathological state where conditions such as obesity can promote an increase in the CB1 ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and thus competition for the CB1 receptor. These data demonstrated that while nimacimab's potency remained relatively stable, the activity of monlunabant when challenged with a higher concentration of a CB1 agonist was significantly impacted.
Dr. Chris Twitty, Chief Scientific Officer of Skye, said, 'These data demonstrate for the first time how nimacimab's allosteric binding to the CB1 receptor is differentiated from the small molecules which bind to the receptor's active orthosteric site. We know that in a disease state such as obesity, the CB1 receptor as well as its natural ligands, AEA and 2-AG, are upregulated. In this diseased state, there may be significant competition for the active binding site. In our in vitro experiment we aimed to recreate this potential situation. The biological impact of these data suggests that when there is significant competition for CB1 binding, the activity of small molecules like monlunabant can be significantly impacted. Clinically this could result in impacting the relationship between pharmacodynamics and pharmacokinetics of the drug, ultimately requiring more of the small molecule to overcome the competition. Alternatively, nimacimab does not compete for the same site as the natural ligands, and our data show that as a result of this allosteric binding, the potency is minimally impacted regardless of the concentration of competing molecules.'
'In the context of CB1 inhibition, we aim to realize the weight loss and metabolic benefits of this mechanism without the neuropsychiatric side effects seen with small molecule drugs. In our estimation, the potential of superior potency of nimacimab in this disease state may offer the widest possible therapeutic window among CB1 inhibitors.'
Figure 2 - Comparison of potency between monlunabant* and nimacimab*** Monlunabant's potency dropped significantly at high agonist levels due to direct competition for the receptor's orthosteric site.** Nimacimab's potency was preserved due to its allosteric binding mechanism that avoids direct competition.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTSInvestor Relationsir@skyebioscience.com(858) 410-0266
LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306
Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action and (v) statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/97a10bc7-3e79-4fbc-9275-d0929f35c403
https://www.globenewswire.com/NewsRoom/AttachmentNg/acfb12e0-c08e-4700-b340-bc19d8a8a712
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
The Future of Work in Oil & Gas Strategic Intelligence Report: Automation is Key for Health and Safety, Digital Twins is Enhancing Operational Efficiency
Discover how future of work technologies, including AI, IoT, and automation, are revolutionizing the oil and gas industry. These advancements enhance operational efficiency, safety, and predictive maintenance, redefine workforce skills, and address industry challenges. Stay ahead with essential insights into this transformation. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: The Future of Work in Oil & Gas" report has been added to offering. This report offers a comprehensive analysis of the future of work in the oil and gas industry, examining how related technologies address four key industry challenges. It identifies which technologies companies should invest in, explore, or ignore across the value chain, highlights leading adopters and specialist vendors in the power industry, and includes case studies. The report also analyzes trends in M&A, hiring, and company filings, and features a thematic scorecard ranking major oil and gas companies on their engagement with future of work of work technologies are dramatically changing how work is performed in the oil and gas industry. As these technologies continue to develop, they will likely be used in tandem. The impact of future of work technologies in oil and gas is already significant and will only grow in the coming future of work is transforming the oil and gas industry Future of work technologies are dramatically changing how work is performed in the oil and gas industry. As these technologies continue to develop, they will likely be used in tandem. Combining automation with Internet of Things (IoT) or artificial intelligence (AI) technologies enables the collection and analysis of data, facilitating predictive maintenance and uninterrupted production, and can aid exploration through seismic data analysis. Consequently, the skillset required in the oil and gas sector is changing. Proficiency in digital tools will become essential for workers, while the significance of manual labor skills will diminish as automated systems take on these tasks. Integrating automation technologies can significantly improve health and safety in a notoriously hazardous industry. In remote and offshore locations, robotics and drones can mitigate risks associated with heights, accessing equipment, and exposure to toxic chemicals and gases. Fully automated systems operate continuously, leading to increased productivity and cost savings. Automation enables real-time monitoring and control from a centralized location, supporting remote asset management. This not only improves operational visibility but also facilitates prompt decision-making and intervention in case of emergencies or anomalies. Digital twins allow companies to monitor, analyze, and optimize their operations in real-time. By integrating data from sensors, equipment, and processes, digital twins provide a comprehensive view of assets, enabling predictive maintenance and performance optimization. This technology helps companies identify potential issues before they occur, reducing downtime and maintenance costs. BP has estimated that optimization analysis, which used to take more than a day, can now be performed in 20 minutes because of the use of digital Highlights The oil and gas industry is currently under pressure from fluctuating oil prices, increasing regulatory requirements, and the energy transition. Future of work technologies could give companies a competitive advantage and allow them to circumvent these challenges. Key technologies that should be prioritized include AI, IoT, connectivity, and robotics, which can significantly enhance operational efficiency and safety. Automation can help improve health and safety in the oil and gas industry by reducing the need for human intervention in high-risk tasks. Robots are increasingly used for tasks such as pipeline inspection, maintenance of equipment in confined spaces, and handling of hazardous materials. The oil and gas industry is facing a workforce shortage. As older workers retire, digital technologies are crucial for knowledge retention. AR headsets allow oil and gas companies to document maintenance and repair tasks, which will be vital in training the next generation of workers. Reasons to Buy The analyst's strategic intelligence ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. This report is essential reading for senior executives to understand how the oil and gas industry will be transformed by future of work technologies, ensuring your company does not get left behind. Key Topics Covered: Executive Summary Players The analyst's Future of Work Framework The Impact of the Future of Work on Oil and Gas Case Studies The Future of Work Timeline Signals Companies Sector Scorecard Glossary Further Reading Thematic Research Methodology List of Tables Key players in the Future of Work Future of Work timeline Future of Work M&A trends Leading Future of Work adopters in the oil and gas industry Specialist future of work vendors in the oil and gas industry Integrated oil and gas scorecard company screen Integrated oil and gas scorecard thematic screen Integrated oil and gas scorecard valuation screen Integrated oil and gas scorecard risk screen Glossary A selection of companies mentioned in this report includes, but is not limited to: 3D Systems (DDD) ABB Aker Solutions ADNOC Aize Alibaba Alphabet Andium ANYbotics Amazon Apple Autodesk AT&T Avathon Baker Hughes Baker Industries Baidu BP Bidgely Bosch Caterpillar Celona Chevron Cloudera Cisco (Webex) CNPC Cyberhawk Dassault Systemes DJI Ecopetrol EDF Eni Epiroc Emerson Equinor ExxonMobil Fugro FANUC Gazprom GM (Cruise) Halliburton Honeywell Huawei Hyundai (Boston Dynamics) IBM Kuwait Petroleum Lenovo Liebherr Lukoil Merge Labs Midea (KUKA) Microsoft Microsoft (Teams/365) Midjourney MOL NIOC NICE Nesh Nvidia OMV Oceaneering OpenAI Parrot Petrobas Petronas PKN Orlen PDVSA Repsol Reliance Industries Rockwell Automation Rokid Rosneft Samsung Electronics Saudi Aramco Sasol Schneider Electric Schneider Electric (Aveva) Shell Siemens SLB Salesforce Salesforce (Slack) Seeq Stem Suncor Tatneft Tesla Teradyne TotalEnergies UiPath Uplight Verizon Vuzix YPF Xiaomi Yuneec XenonStack For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Employee Benefits in Ireland 2025: Comprehensive Study Highlights Key State and Private Benefits for Irish Workers
Discover comprehensive insights into Ireland's employee benefits landscape, including state, compulsory, and private benefits. Analyze the intricate social security framework, key regulatory acts, and the role of central institutions. Enhance strategic decisions with detailed regional benefits and market insights. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Employee Benefits in Ireland 2025" report has been added to report provides in-depth industry analysis, information, and insights of the employee benefits in Ireland, including an overview of the state and compulsory benefits in Ireland, detailed information about the private benefits in Ireland, insights on various central institutions responsible for the administration of the different branches of social security and the regulatory framework of the employee benefits in Irish social security system covers company employees, self-employed individuals, the unemployed, people with less than minimum resources, and dependent family members of deceased employees. The Irish social welfare system is divided into social insurance payments, means-tested payments, and universal payments. The payment of social insurance is mandatory; both employers and employees must contribute Pay-Related Social Insurance (PRSI) contributions to the Social Insurance Fund. Self-employed persons pay Class S social insurance contributions directly to the Revenue Commissioners, although these are not required to be paid after the age of 66. A range of state benefits is available for Irish residents, which are subject to several conditions other than social insurance contribution requirements. Companies across the country also provide customized private benefits to their employees as a supplement to state Highlights The Minimum Notice and Terms of Employment Act 1973, the Organization of Working Time Act 1997, the Payment of Wages Act 1991, and the Maternity Protection Act 1994 are responsible for the functioning of the overall social security system. A person's national insurance contribution is determined based on their income. An insured person who is unemployed or unable to work and whose benefits have been exhausted is entitled to a credited contribution. Employers offer voluntary retirement benefits via voluntary occupational DC pension plans, which are prevalent in the country, such as Personal Retirement Savings Accounts (PRSAs), Retirement Annuity Contracts (RACs), Approved Retirement Funds (ARFs), and Personal Retirement Bonds (PRBs). This report provides a detailed analysis of employee benefits in Ireland: It offers a detailed analysis of the key government-sponsored employee benefits, along with private benefits It covers an exhaustive list of employee benefits, including retirement benefits, death in service, long-term disability benefits, medical benefits, workmen's compensation insurance, maternity and paternity benefits, family benefits, unemployment benefits, long-term care benefits, minimum resource benefits, leaves and holidays, and private benefits It highlights the economic and regulatory situations relating to employee benefits in Ireland Reasons to Buy Make strategic decisions using in-depth information related to employee benefits in the country Assess employee benefits of the market, including state and compulsory benefits and private benefits Gain insights into the key employee benefit schemes offered by private employers in the country Gain insights into key organizations governing employee benefits market, and their impact on companies Key Topics Covered: 1. Executive Summary2. Introduction3. Country Statistics4. Overview of Employee Benefits in Ireland5. Regulations6. State and Compulsory Benefits6.1 Retirement Benefits Introduction Eligibility Benefits Payment options Contribution 6.2 Death in Service Introduction Eligibility Benefits Payment options Contribution 6.3 Long-Term Disability Benefits Introduction Eligibility Benefits Payment options Contribution 6.4 Short-Term Sickness Benefits Introduction Eligibility Benefits Payment options Contribution 6.5 Medical Benefits Introduction Eligibility Benefits Payment options Contribution 6.6 Workers' Compensation insurance Introduction Eligibility Benefits Payment options Contribution 6.7 Maternity and Paternity Benefits Introduction Eligibility Benefits Payment options Contribution 6.8 Other Benefits Family Benefits Unemployment benefits Long-Term Care Benefits Minimum Resources Benefits Leaves and Holidays 7. Private Benefits7.1 Retirement Benefits7.2 Death Benefits7.3 Disability Benefits7.4 Medical Benefits7.5 Accidental Death and Dismemberment Benefits7.6 Other Benefits For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Mining Industry Quarterly Review, Q4 2024 & Full Year - Top 18 Mining Companies Invest $69.1B in 2024; Forecasted Increase for 2025
"Mining Quarterly Review - Q4 2024 & Full Year" analyzes global mining trends, covering commodities, production, and capital expenditure. Indonesia achieved record coal outputs while boosting its nickel industry. Glencore led in coal production growth, driven by key acquisitions. Top miners spent $69.1B in 2024, with a 2025 rise forecasted. Key regions include Canada, Australia, South Africa, and the US. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Mining Quarterly Review - Q4 2024 & Full Year" report has been added to offering. The report contains an overview of the key commodities in the mining industry including coal, iron ore, copper, gold, nickel, lead, zinc, uranium and lithium. It provides detailed information on prices, production by country, production by company, development projects update, capital expenditure, and demand "Mining Quarterly Review - Q4 2024 & Full Year" provides a comprehensive coverage on the global mining industry. It provides commodity trends covering price trends, production, capital expenditure of leading miners, development projects momentum, development projects by commodity, country, company and stage. The report also includes a demand drivers section providing information on factors that are affecting the global mining industry. It further provides updates on emissions, safety in mining, regulatory, developments in mining for Q4 2024 & Full Year, European Union's industrial production, US' industrial production, China's industrial production growth rate, China's Manufacturing PMI .While maintaining strong coal production, Indonesia is also navigating the global energy transition. This involves balancing coal output with the development of its nickel industry, crucial for EV batteries. Indonesia surpassed its 2024 coal production targets, reaching record highs to 836Mt, driven by both domestic and international demand. In Q4 2024, Glencore recorded the highest coal production growth, significantly outpacing its competitors. Yanzhou, Coal India and China Shenhua Energy also registered growth, though at a much smaller scale. Glencore experienced a significant increase in metallurgical coal production, rising by 18.9% compared to the same period in 2023. This substantial growth was primarily attributable to the acquisition of Canadian steelmaking operations, Elk Valley Resources (EVR), in July 2024. After 0.82% of projects in the development stages advanced in Q3 2024, the development projects momentum improved to 1.37% in Q4 2024. Some 37 projects advanced during this quarter, of which 16 were in Canada, Australia, South Africa and the US, 2024, the world's top 18 mining companies collectively invested over $69.1B in capital expenditures. Companies' projections for 2025 indicate a 5.1% increase to $72.7B for the same 18 to Buy To gain an understanding of the quarterly changes in the global mining industry, relevant driving factors To understand historical and forecast trends on key commodities To identify key players in the global mining industry To identify major development projects momentum by region To identify the trend in capital expenditure spent by leading miners To understand the factors influencing demand drivers of key commodities Key Topics Covered: Overview Macroeconomic trends Commodity trends Coal Iron ore Copper Gold Nickel Lead Zinc Uranium Lithium Development projects update Capital expenditure Demand drivers Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio